TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioNTech SE ( (BNTX) ) has issued an update.
On December 3, 2025, BioNTech SE announced that it has satisfied the minimum condition of its exchange offer for CureVac N.V., with 81.74% of CureVac’s shares tendered. The subsequent offering period has commenced, allowing remaining CureVac shareholders to tender their shares until December 18, 2025. The completion of this exchange offer will lead to a post-offer reorganization, impacting the tradability of CureVac shares and subjecting non-tendering shareholders to a Dutch dividend withholding tax. This strategic move strengthens BioNTech’s position in the biopharmaceutical industry by expanding its portfolio and market reach.
The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
Biopharmaceutical New Technologies (BioNTech) is a global next-generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. The company focuses on developing mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies. BioNTech is also involved in researching mRNA vaccine candidates for infectious diseases, collaborating with multiple global and specialized pharmaceutical companies.
Average Trading Volume: 981,629
Technical Sentiment Signal: Strong Sell
Current Market Cap: $23.11B
See more data about BNTX stock on TipRanks’ Stock Analysis page.